Fig. 1: Decreased levels of astrocyte elevated gene-1 (AEG-1) in the postmortem substantia nigra (SN) of patients with Parkinson’s disease (PD) and the SN of 6-hydroxydopamine (6-OHDA)-treated mice.
From: Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo
a Description of the human postmortem SN tissue. b Immunohistochemistry for AEG-1 in the human SN. Scale bar, 50 μm. The square insets in the left panels contain magnifications of the photomicrographs in the right panels. Scale bar, 20 μm. The blue arrows indicate AEG-1 immunoreactivity, and the brown arrows indicate neuromelanin immunoreactivity. c Western blot analysis of the levels of tyrosine hydroxylase (TH) and AEG-1 in the human SN. *p = 0.022 and #p = 0.033 vs. age-matched controls (CON) (t-test; n = 4 for each group). d Representative sections showing AEG-1 expression (with Nissl counterstaining) in the mouse SN pars compacta (SNpc), which is outlined by the dotted lines. Scale bar, 20 μm. The square insets in the left contain magnifications of the photomicrographs in the right panels. Scale bar, 20 μm. e Western blot analyses of the levels of AEG-1 and TH in the mouse SN. AA ascorbic acid. *p = 0.024 and **p = 0.001 vs. intact CON; #p < 0.001 for TH, significantly different from CON [one-way analysis of variance (ANOVA) with Tukey’s post hoc test; n = 4 for each group]. f Description of the human postmortem hippocampal tissue. g Western blot analyses of the levels of AEG-1 and neuronal nuclei (NeuN) in the hippocampus of patients with Alzheimer’s disease (AD) and CON. Please note that of the levels of AEG-1 are not decreased in the postmortem hippocampus of patients with AD compared with CON. #p = 0.001 vs. CON (t-test; n = 5 for each group)
